Drugs / ASP8477
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02220777 | Nov 2010 → May 2011 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02065349 Comparator | Feb 2014 → Feb 2015 | diabetic polyneuropathy, neuropathy, painful, postherpetic neuralgia | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP8477 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02065349 ↗ |
| Action | Inhibit | “ASP8477 is known to have the strongest inhibitory effect on CYP2C19.” NCT02220777 ↗ |
| Modality | Small molecule | — CHEMBL5095212 ↗ |
| Route | Oral | “oral” NCT02065349 ↗ |
| Target | CYP2C19 | “ASP8477 is known to have the strongest inhibitory effect on CYP2C19.” NCT02220777 ↗ |